Hester Biosciences announced its Q3 and 9M FY25 financial results, revealing a 14% increase in standalone sales for the nine-month period, but a 4% decline for Q3. Consolidated profit surged by 85% over the nine months, while Q3 showed an impressive rise of 184%.